Format

Send to

Choose Destination
Am J Cardiol. 2016 Aug 15;118(4):572-7. doi: 10.1016/j.amjcard.2016.05.052. Epub 2016 May 28.

Comparison of Results of Transcatheter Aortic Valve Implantation in Patients With Versus Without Active Cancer.

Author information

1
Department of Cardiology, Teikyo University School of Medicine, Tokyo, Japan. Electronic address: yusuke0831@gmail.com.
2
Department of Cardiology, Teikyo University School of Medicine, Tokyo, Japan.
3
Department of Cardiology, Kokura Memorial Hospital, Fukuoka, Japan.
4
Department of Cardiology, Sendai Kousei Hospital, Miyagi, Japan.
5
Department of Cardiology, Saiseikai Yokohama City Eastern Hospital, Kanagawa, Japan.
6
Department of Cardiology, New Tokyo Hospital, Chiba, Japan.
7
Department of Cardiology, Shonan Kamakura General Hospital, Kanagawa, Japan.
8
Department of Cardiology, Toyohashi Heart Center, Aichi, Japan; Department of Cardiology, Nagoya Heart Center, Aichi, Japan.
9
Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.

Abstract

The aim of this study was to evaluate postprocedural and midterm outcomes of transcatheter aortic valve implantation (TAVI) in patients with aortic stenosis and active cancer. From October 2013 to August 2015, a total of 749 patients undergoing TAVI using the Edwards Sapien XT prosthesis (Edwards Lifesciences, Irvine, California) were prospectively included in the OCEAN-TAVI registry from 8 Japanese centers. A total of 47 patients (44.7% men; median age 83 years) had active cancer. The transfemoral approach was implemented in 85.1% of patients in the cancer group and 78.1% in the noncancer group (p = 0.22). The occurrence of major vascular complication (4.3% vs 7.5%, p = 0.24), life-threatening bleeding (2.1% vs 7.1%, p = 0.15), and major bleeding (8.5% vs 13%, p = 0.38) was similar between the cancer and noncancer groups. No significant differences were observed regarding device success (100% vs 96.2%, p = 0.17) or 30-day survival (95.7% vs 97.3%, p = 0.38). No difference in midterm survival was found between the patients with cancer and without cancer (log-rank, p = 0.42), regardless of advanced or limited cancer (log-rank, p = 0.68). In a multivariable Cox proportional hazard regression analysis, cancer metastasis was one of the most significant predictors of late mortality (hazard ratio 4.73, 95% CI 1.12 to 20.0; p = 0.035). In conclusion, patients with cancer with severe aortic stenosis who underwent TAVI had similar acute outcomes and midterm survival rates compared with patients without cancer. Cancer metastasis was associated with increased mortality after TAVI.

PMID:
27324159
DOI:
10.1016/j.amjcard.2016.05.052
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center